Bookmark

Add to MyYahoo RSS

Cubist Pharmaceuticals News

News on Cubist Pharmaceuticals (Ticker: CBST) continually updated from thousands of sources around the net.

Tuesday Aug 26 | Freshnews

Cubist to Present New Data from Antibiotics Portfolio at 54th...

Cubist Pharmaceuticals, Inc. today announced that it will present new data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy , September 5-9 in Washington, D.C. Data highlighted will offer insights into Cubist's commitment to identifying treatments for drug-resistant Gram-positive and Gram-negative bacteria that cause ... (more)

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals, Healthcare Law, Food and Drug Administration, Law, Urinary Tract Infections, Health

Mon Aug 25, 2014

Business Wire

Cubist to Present at Morgan Stanley Global Healthcare Conference

The presentation will be held at the Grand Hyatt New York hotel in New York City on Monday, September 8, 2014 at 10:30 a.m. Eastern Time.

Comment?

Related Topix: Cubist Pharmaceuticals, Biotech, Medicine, Healthcare Industry

Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

A live webcast and replay will be a... )--Research and Markets has announced the addition of the "MIMO-based Communications Systems Technologies, Market... )--Artisan announced the availability of in-app messaging capabilities, which are integrated into its Mobile Experience Management platform for mobile app analytics, per... )--Accenture was ... (more)

Comment?

Related Topix: E*Trade, Biotech, Medicine, Healthcare Industry

Fri Aug 22, 2014

Customer Interaction Solutions

Allergan Receives Written Requests from Pershing Square; Cubist...

We are pleased to receive MAA acceptance for ceftolozane/tazobactam and look forward to working with the EMA on this important review," said Steven Gilman, Ph.D., Executive Vice President of Research and Development and Chief Scientific Officer of Cubist.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, E. Coli, Health, Food and Drug Administration, Drugs, Aastrom Biosciences, Marijuana

BioSpace

Cubist Pharmaceuticals, Inc. Announces EMA Acceptance Of...

Cubist Pharmaceuticals, Inc. today announced that the European Medicines Agency has accepted for review the Company's Marketing Authorization Application for its investigational antibiotic ceftolozane/tazobactam.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Wed Aug 20, 2014

JD Supra

The Double Whammy: Cubist's Recent FCPA Disclosure

In the FCPA enforcement world, corporate disclosures of potential violations carrying significant messages.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals, Optimer Pharmaceuticals, Healthcare Law, Law

AmericanBankingNews.com

Cubist Pharmaceuticals Director Nancy J. Hutson Sells 9,000 Shares

Cubist Pharmaceuticals Director Nancy J. Hutson sold 9,000 shares of the stock in a transaction dated Monday, August 18th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals

AmericanBankingNews.com

Insider Selling: Cubist Pharmaceuticals COO Unloads 1,003 Shares of Stock

Cubist Pharmaceuticals COO Robert J. Perez sold 1,003 shares of Cubist Pharmaceuticals stock on the open market in a transaction that occurred on Monday, August 18th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals

US Pharmacist

Vancomycin-Resistant Enterococcus

DISCLAIMER: M.P., J.S., N.D., and A.R. are employed by Bouve College of Health Sciences as postdoctoral fellows with Cubist Pharmaceuticals, Inc. ABSTRACT: Vancomycin-resistant Enterococcus is a major cause of hospital-acquired infections in the United States.

Comment?

Related Topix: Biotech, Healthcare Industry, Microbiology, Biology, Science

Mon Aug 18, 2014

AmericanBankingNews.com

Cubist Pharmaceuticals Director Sells $585,000 in Stock

Cubist Pharmaceuticals Director Nancy J. Hutson unloaded 9,000 shares of the company's stock in a transaction dated Monday, August 18th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals

AmericanBankingNews.com

Cubist Pharmaceuticals COO Unloads $63,871 in Stock

Cubist Pharmaceuticals COO Robert J. Perez unloaded 1,003 shares of the stock in a transaction that occurred on Monday, August 18th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals

AmericanBankingNews.com

Cubist Pharmaceuticals Stock Rating Lowered by Zacks

They currently have a $58.00 price target on the stock. Zacks 's price objective points to a potential downside of 8.50% from the stock's previous close.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals

BioSpace

Cubist Pharmaceuticals, Inc. Could Be An Acquisition Target For Needy Pfizer Inc.

The timing may be right for a takeover of Cubist Pharmaceuticals Inc. The rising threat from drug-resistant germs and increasing calls from global health groups for more potent antibiotics is placing a premium on companies such as Cubist.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Thu Aug 14, 2014

Seeking Alpha

Did The Medicines Company Trump Cellceutix And Others In A $1B-Plus Skin Infection Market?

Cellceutix's Brilacidin flagship one step antibiotic potentially simplifies patient results with a single dose possibly making Brilacidin the physician's first choice for fighting skin infections and oral mucositis.

Comment?

Related Topix: Biotech, Medicines Company The, Medicine, Healthcare Industry, MRSA, Health, Healthcare Law, Law, Food and Drug Administration

Mon Aug 11, 2014

BioSpace

Cubist Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall Of...

Cubist Pharmaceuticals, Inc. today announced it is voluntarily recalling nine lots of CUBICINA to the user level following complaints of foreign particulate matter in reconstituted vials.

Comment?

Related Topix: Cubist Pharmaceuticals, Biotech, Medicine, Healthcare Industry

In-PharmaTechnologist.com

CMO issues persist as Cubist announces third recall for potential glass in antibiotic

For the third time since last August, Cubist Pharmaceuticals has recalled lots of its antibiotic Cubicin injection due to the potential of glass particulates in a manufacturing line produced by an unnamed CMO .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals

Fri Aug 08, 2014

Pharmaceutical Technology

Cubist Pharmaceuticals Recalls CUBICIN

FDA is reporting that Cubist Pharmaceuticals has announced it is voluntarily recalling certain lots of CUBICIN to the user level due to the potential presence of glass particulate matter in vials produced by a contract manufacturer.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals

Thu Aug 07, 2014

P&T Community

FDA Approves Orbactiv (Oritavancin) for Skin Infections

The FDA has approved Orbactiv for injection for the treatment of adults with acute bacterial skin and skin-structure infections caused by susceptible designated Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus .

Comment?

Related Topix: Biotech, Medicines Company The, Medicine, Healthcare Industry, MRSA, Health, Cubist Pharmaceuticals

Wed Aug 06, 2014

Pharmaceutical Processing

Cubist Pharmaceuticals Issues Voluntary U.S. Recall of Certain Lots of CUBICIN

Cubist Pharmaceuticals today announced it is voluntarily recalling certain lots of CUBICINA to the user level due to the potential presence of glass particulate matter in vials produced by a contract manufacturer.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals

Freshnews

Cubist Pharmaceuticals Issues Voluntary U.S. Recall of Certain Lots...

Cubist Pharmaceuticals, Inc. today announced it is voluntarily recalling certain lots of CUBICIN to the user level due to the potential presence of glass particulate matter in vials produced by a contract manufacturer.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••